Last reviewed · How we verify
BX004
At a glance
| Generic name | BX004 |
|---|---|
| Also known as | Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa |
| Sponsor | BiomX Ltd |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study With Phage for CF Subjects With Pseudomonas Lung Infection (PHASE2)
- Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BX004 CI brief — competitive landscape report
- BX004 updates RSS · CI watch RSS
- BiomX Ltd portfolio CI